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A B S T R A C T
Eye drops are widely accepted as formulations for targeting the anterior segment notwithstanding their limitations in
terms of bioavailability. The unique structure of the eye requires specially-designed formulations able to favor the phar-
macokinetic profile of administered drugs, mainly minimizing the influence of ocular barriers. Nanotechnology-based
delivery systems lead to significant technological and therapeutical advantages in ophthalmic therapy.
The aim of the present study was to determine whether tobramycin as ion-pair incorporated in mucoadhesive Solid
Lipid Nanoparticles (SLN) reaches the inner parts of the eye favoring drug activity.
After technological characterization of the tobramycin entrapped SLN formulation (Tobra-SLN), a pharmacokinetic
study in rabbits after topical instillation and intravenous administration of the formulation has been carried out. In ad-
dition, the intracellular activity of Tobra-SLN formulation against phagocytosed Pseudomonas aeruginosa was investi-
gated.
The SLN were spherical in shape, and showed a hydrodynamic diameter of about 80 nm, a negative zeta potential
(−25.7 mV) with a polydispersity index of 0.15, representative of a colloidal dispersion with high quality, characterized
by an unimodal relatively narrow size distribution. As demonstrated by FTIR and DSC, tobramycin ion-pair could be
concentrated into lipid inner core of SLN, without interaction with the stearic acid, thus promoting a slow and constant
drug release profile in the dissolution medium.
Surprisingly, the drug concentration was significantly higher in all ocular tissues after ocular and intravenous admin-
istration of Tobra-SLN formulation with respect to reference formulations and only Tobra-SLN allowed the penetration
of drug into retina. Furthermore, the use of Tobra-SLN resulted in both higher intraphagocytic antibiotic concentrations
in polymorphonuclear granulocytes and greater bactericidal activity against intracellular Pseudomonas aeruginosa, prob-
ably due to the ability of Tobra-SLN to penetrate either into phagocytic cells, or alternatively to cross bacterial barrier.
The present study broadens the knowledge on the use of SLN as carriers for ocular drug delivery to the posterior
chamber and might open new avenues for treatment of ocular infections, representing a strategy to overcome the micro-
bial resistance.
© 2016 Published by Elsevier Ltd.
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1. Introduction
The eye is considered a complex and delicate organ of the human
body that represents a very challenging issue in drug delivery. Eye
drops are widely accepted as formulations for targeting the anterior
segment notwithstanding their limitations in terms of bioavailability
for extensive pre-corneal loss due to blinking, rapid washout by tear-
ing, drainage through the naso-lacrimal duct, non-productive absorp-
tion [1–4]. Furthermore, eye drops capability to treat vitreoretinal dis-
eases, such as bacterial infections, endophthalmitis, cytomegalovirus
retinitis (CMV), uveitis, proliferative vitreoretinopathy (PVR), dia-
betic retinopathy, and age-related macular degeneration (AMD) is
⁎ Corresponding author.
Email address: roberta.cavalli@unito.it (M.t.a.V.T.b.t.a.R.C. Cavalli)
worthless because of poor drug penetration in the posterior segment
[1,4–6]. The main challenges in ocular therapy are represented by the
reduction in precorneal drainage of the instilled formulations and the
overcoming of the protective barriers of eye to reach a sufficient drug
concentrations at the site of action. The unique structure of the eye
requires specially-designed carriers able to optimize the pharmaco-
kinetic behavior of topically administered drugs, mainly minimizing
the influence of ocular barriers [1,3,5–9]. The corneal layers, in par-
ticular the epithelium and stroma, are considered the major barriers
for absorption of topically applied drugs, which should have amphi-
pathic nature, in order to permeate through the lipophilic/hydrophilic
layers. In addition, the sclera, mainly consisting of collagen fibers and
proteoglycans embedded in an extracellular matrix, is considered to
be comparable in permeability to the corneal stroma. The permeabil-
ity of drug molecules across the sclera is inversely proportional to
the molecular radius and to the charge of the drug molecule: posi
http://dx.doi.org/10.1016/j.ejpb.2016.10.006
0939-6411/© 2016 Published by Elsevier Ltd.
UN
CO
RR
EC
TE
D
PR
OO
F
2 European Journal of Pharmaceutics and Biopharmaceutics xxx (2016) xxx-xxx
tively charged molecules exhibit scarce permeability, presumably for
their binding to the negatively charged proteoglycan matrix [9–11].
The systemic route represents a successful treatment for ocular dis-
eases involving the anterior segment or the ocular surface, but it is
not suitable to treat vitreoretinal diseases. In fact, the outer and inner
blood-retinal barriers, formed respectively by retinal pigment epithe-
lium and retinal vascular endothelium, inhibit the intraocular penetra-
tion of drugs when applied systemically [3,12,13].
Nanotechnology-based delivery systems (i.e. nanocapsules, mi-
croemulsions, liposomes, nanomicelles and lipid nanoparticles) lead
to significant technological and therapeutical advantages in oph-
thalmic therapy, as increase in precorneal drug retention time, sus-
tained drug release, reduction in administration frequency, reduced
drug toxicity, targeted delivery to specific eye tissues. Furthermore,
micro/nanocarriers can be generally administered as dispersion in the
form of eye drops without causing blurred vision and irritation
[7,8,13–16]. All these aspects cause an improvement in bioavailability
of drugs and in the patient compliance. Among all nanocarriers, lipid
carriers, in particular SLN, were extensively investigated as promis-
ing delivery systems for hydrophilic or lipophilic ophthalmic drugs
[8,17–23]. Besides being a droppable preparation and improving oc-
ular bioavailability of drugs, lipid nanocarriers have the advantage to
reduce both the leakage of drugs encapsulated, as for liposomes, and
the instability during storage typical of emulsions, polymeric nanopar-
ticles and liposomes.
In previous works, we showed that solid SLN modified the phar-
macokinetic parameters and the distribution of several incorporated
drugs in the biological tissues, increasing their passage through barri-
ers such as the blood brain barrier [24–26]. In detail, we observed that
a SLN dispersion containing the antibacterial tobramycin significantly
enhanced the drug bioavailability in the aqueous humor [27] and that
pilocarpine incorporated in SLN tripled the miotic effect of the drug in
comparison with the commercial formulation [28]. Recent reports re-
ferred on the positive behavior of the association between the drug-en-
trapped SLN carriers prepared with different lipidic components and
innovative “in situ” gel forming vehicles [29] and on the improved ef-
ficacy of SLN by incorporating hyaluronic acid and protamine to ob-
tain a versatile carrier for gene therapy [30].
Even if in the last ten years SLN have been studied extensively
and several manuscripts reported the advantage obtained by their use
as delivery systems for many ophthalmic drugs (anti-inflammatory,
antiglaucoma, antibacterial, antifungal), natural extracts, antioxidant
molecules and gene therapy [9,20,21,30–35], in vivo studies are al-
most rare, while they should be helpful to establish the real therapeu-
tical potential of SLN as ocular drug delivery.
The aim of the present study was to broaden the knowledge on the
ocular delivery of tobramycin on rabbits by determining whether to-
bramycin incorporated in a mucoadhesive SLN dispersion is able to
reach the inner parts of the eye. Hence, a pharmacokinetic study in
rabbits after ocular instillation and intravenous administration of the
SLN has been carried out. Since the entrance of antimicrobial agents
into phagocytic cells in association with cellular bactericidal mecha-
nisms is a prerequisite for their activity, we also investigated the intra-
cellular activity of tobramycin in comparison with SLN formulations
against phagocytosed Pseudomonas aeruginosa, which is responsi-
ble for numerous eye infections [36,37], in order to demonstrate all
their possible benefits. Furthermore, the physical and chemical stabil-
ity over the time of drug-loaded SLN has been investigated.
2. Materials and methods
2.1. Materials
Stearic acid and 1-fluoro-2,6 dinitrobenzene were from Fluka
(Buchs, Switzerland); Epikuron 200 (soya phosphatidylcholine 95%)
was kindly provided by Cargill (Hamburg, Germany); tobramycin
base, mucin from porcine stomach type III, type VII alkaline phos-
phatase and fluorescamine were from Sigma Chemical Co. (Missouri,
USA), and taurocholate sodium salt was kindly provided by PCA
(Basaluzzo, Italy). Sodium hexadecylphosphate was prepared as indi-
cated by Brown [38]. The commercial eye drops Tobral® (0.3% of
tobramycin, Alcon Italia S.p.A., Italy) was used as control. The other
chemicals were of analytical grade.
2.2. Animals
All experiments were carried out on male New Zealand albino rab-
bits of 2.8–3.5 kg (Pampaloni Rabbitry, Fauglia, Italy). The animals
were housed in singly standard cages in a light-controlled room (10 h
dark/14 h light cycle) at 19 ± 1 °C and 50 ± 5% RH and were given
a standard pellet diet and water ad libitum. During the experiments
the rabbits were placed in restraining boxes but their eyes move-
ments were not restricted. The rabbits were treated in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and Vi-
sion Research, following a protocol approved by the Ethical-Scientific
Committee of the University of Pisa and under veterinary supervision.
Eight groups of animals, each of three rabbits, were used for the
different treatments.
2.3. Preparation of Solid Lipid Nanoparticles incorporating
tobramycin (Tobra-SLN)
Solid lipid nanoparticles containing the tobramycin as complex
(Tobra-SLN) were prepared, as tuned previously by us, from o/w mi-
croemulsions consisting of stearic acid as internal phase (0.70 mmol),
Epikuron 200 as surfactant (0.14 mmol), sodium taurocholate as co-
surfactant (0.72 mmol), and deionized water as continuous phase
(110.10 mmol). The drug was added to the microemulsion as ion-pair
complex with hexadecylphosphate in a 1:2 tobramycin:hexade-
cylphosphate molar ratio to increase the lipophilicity of tobramycin.
The final amount of tobramycin complex was 0.05 mmol [27]. The
ion-pair complex favored partition of tobramycin in the oil phase of
the microemulsion and was prepared using a co-precipitation method
with hexadecylphosphoric acid as tobramycin counter ion [39,40]. To-
bra-SLN aqueous dispersions were obtained by dispersing warm o/w
microemulsion in cold water at a 1:10 microemulsion:water (v/v) ra-
tio under mechanical stirring. Dispersions were washed three times
by diaultrafiltration with TCF2 system (Amicon, Danvers, USA) us-
ing a Diaflo YM 100 membrane (cutoff 100,000 Da) to remove the
majority of the cosurfactant used to obtain the microemulsion. Af-
ter the purification, Tobra-SLN dispersion was freeze-dried and sub-
sequently dispersed to obtain the required final concentration of to-
bramycin of 2.0 mg/mL. The quantitative determination of tobramycin
incorporated in Tobra-SLN was carried out on a freeze-dried sample
of Tobra-SLN dispersion after dissolution in methanol [27].
To perform the biological studies on rabbits, the to-
bramycin-loaded SLN formulation was packaged in vials and steril-
ized by autoclaving at 121 °C (2 bar) for 15 min.
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2.4. Preparation of tobramycin reference solution (Tobra-SOL)
Tobramycin reference solution was prepared in physiological so-
lution (0.9% w/w of sodium chloride) at a concentration of 2.0 mg/
mL and sterilized by microfiltration (0.22 μm, Millex-GS syringe fil-
ter unit, Merck Millipore, Germany) under laminar flow cup before
each in vivo experiment.
2.5. Quantitative determination of tobramycin
The amount of tobramycin incorporated in Tobra-SLN was de-
termined in accordance with analytical protocols previously applied
by us, by spectrophotometric method, using a DU 730 spectropho-
tometer (Beckman Coulter, Italy), on an exactly weighed sample of
freeze-dried Tobra-SLN dissolved in methanol before the derivatiza-
tion reaction with fluorescamine according to Cavalli et al. [27].
Quantitative determination of tobramycin in the aqueous samples
of in vitro release study was carried out by an indirect spectropho-
tometric method (λex = 390 nm) using fluorescamine as derivatizing
agent according to Tekkeli et al. [41].
Tobramycin in the samples of aqueous humor, vitreous humor and
retina was quantified by a reverse-phase HPLC method [25–27,42]
with a UV detector (λ = 350 nm) using 1-fluoro 2,4-dinitrobenzene to
derivatize tobramycin. The mobile phase based on acetonitrile:phos-
phoric acid (5.0 g/L) 70:30 v/v was pumped in HPLC systems (Shi-
madzu, Italy) consisted of a LC-10 AC pump, 20 μL loop injector (Re-
odyne, Sigma-Aldrich, Italy) and a C-R6A recorder. The column was
a Symmetry C-18 column (250 nm × 4.6 mm, Waters). The biologi-
cal samples were prepared as described elsewhere [23]. Briefly, tis-
sue samples were thawed and sonicated for 30 min after adding sterile
phosphate buffer solution pH = 7.4, 66.7 mM (PBS). A 100 μL por-
tion was added to 1.0 mL of methanol, sonicated for 15 min and main-
tained for 30 min at 65 °C. The mixture was diluted with 0.9 mL of
PBS, vortexed for 1 min and finally centrifuged at 5000g for 10 min.
180 μL was then transferred to a vial containing 80 μL of 1-flu-
oro-2,4-dinitrobenzene prepared in methanol (180 mg/mL), 60 μL of
0.1 M borate buffer (pH 9.3) and 680 μL of methanol. The vial was
vortexed for 1 min, heated to 80 °C for 45 min and cooled to room
temperature before HPLC analysis. A linear calibration curve with a
good correlation coefficient (r2 = 0.9980) was obtained in the concen-
tration range 50–600 ng/mL.
2.6. Characterization of solid lipid nanoparticles
The mean diameter, polydispersity index and zeta potential of
Tobra-SLN dispersion were determined by photo correlation spec-
troscopy (PCS) using a 90 Plus instrument (Brookhaven, New York,
USA). For mean diameter and polydispersity index the measurements
were performed at a fixed angle of 90° and a temperature of 25 °C.
Both SLN water dispersions were diluted 1:30 v/v before analysis and
each batch was analyzed ten times [43]. For zeta potential determi-
nation, samples of SLN were diluted with KCl 0.1 mM and placed in
the electrophoretic cell, where an electric field of 15.24 V/cm was ap-
plied. Each sample was analyzed at least in triplicate. The measured
electrophoretic mobility was converted into zeta potential using the
Smoluchowski equation [44].
The evaluation of the interaction between tobramycin and lipid
component of SLN was determined on samples of pure drug, stearic
acid, ion-complex and Tobra-SLN, using FTIR analysis. The spectra
were recorded on a Perkin Elmer 2000 instrument in the range be-
tween 400 and 4000 cm−1.
2.7. Transmission electron microscopy analysis
Transmission electron microscopy (TEM) analysis was performed
using a Philips CM10 instrument (Eindhoven, Holland). For this pur-
pose SLN aqueous dispersions were diluted 1:40, stained with a 2% v/
v aqueous solution of osmium tetraoxide and sprayed on a copper grid.
2.8. Thermal analysis of freeze-dried SLN
Differential Scanning Calorimetry (DSC) analysis was performed
using a DSC/7 differential scanning calorimeter (Perkin-Elmer, Con-
necticut, USA) equipped with a TAC 7/DX instrument controller.
The instrument was calibrated with indium for melting point and
heat of fusion. A heating rate of 20 °C/min was used in the range of
25–240 °C. About 5 mg of freeze-dried samples of SLN was taken in
the standard aluminum sample pans for analysis and an empty pan was
used as reference in each case. Analyses were performed under nitro-
gen purge; triple runs were carried out on each sample.
2.9. In vitro release kinetic studies
Exactly weight freeze-dried samples of Tobra-SLN were mixed
with 66.7 mM phosphate buffer (pH 7.4) to obtain dispersion with
drug concentrations of 0.43 mM that was placed in the donor compart-
ment of a multi-compartment rotating cell. An aqueous solution of to-
bramycin was used at the same concentration and pH as control. A hy-
drophilic dialysis membrane (cut-off 12,000, Dialysis tubing, Sigma
Chem. Co., Missouri, USA) was used to separate the receptor com-
partment containing phosphate buffer at the same concentration and
pH. Each experiment lasted two hours and at fixed times the recep-
tor buffer was completely withdrawn and replaced with fresh buffer.
The withdrawn solutions were then analyzed by HPLC to determine
the amount of tobramycin.
The tobramycin release data were analyzed by a relationship pro-
posed by Ritger and Peppas [45] and using Prism software (GraphPad
Software Inc., San Diego, CA, USA).
2.10. Physical and chemical stability of drug-loaded SLN over time
The stability of Tobra-SLN dispersion packaged in vials, sterilized
by autoclaving and maintained at 4 °C, was evaluated over time ana-
lyzing their average diameters and polydispersity index by PCS after
1, 24, and 48 h and after 6, 12 and 24 months. At the same times the
drug concentration of tobramycin in SLN was evaluated by HPLC.
2.11. In vitro determination of Tobra-SLN interaction with mucin
Tobra-SLN mucoadhesion capacity was determined in vitro, eval-
uating the interaction with porcine mucin [46].
The interaction was studied by incubation of mucin and SLN (1:4
weight ratio) in PBS at pH = 7.4. The incubation was carried out un-
der stirring for 1 h at temperature of 37 °C. Then, the system was
centrifuged and the supernatant was used for the measurement of the
free mucin content, evaluating the transmittance value using a DU
730 Beckman spectrophotometer.
The amount of mucin interacting with the nanoparticles was cal-
culated from a calibration curve. For this purpose, a series of mucin
aqueous solutions with different concentrations (0.025, 0.05, 0.1, 0.2
and 0.5 mg/mL) were prepared. The amount of the mucin adsorbed
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on the nanoparticles was determined as a difference between its initial
mucin concentration and the concentration found in the supernatant.
2.12. In vivo experiments: intravenous administration of the
formulations
Four different groups of animals, each of three rabbits, were treated
by intravenous injection in the ear marginal vein with (a) Tobra-SLN
and (b) Tobra-SOL (reference solution) formulations, both at a dose
of 2 mg/kg. After 1 and 3 h the rabbits were euthanized with an in-
travenous dose of sodium pentobarbital (Pentothal sodium, Farmaceu-
tici Gellini, Aprilia, Italy) and about 100 μL of aqueous humor was
aspired from the anterior chamber of each eye and transferred into
microtubes before HPLC analysis. Then, the eyes were enucleated,
washed with saline solution and dissected to isolate and harvest indi-
vidual tissues, including vitreous humor and retina. All the samples
were stored at −20 °C until quantitative analysis.
2.13. In vivo experiments: topical ocular administration of the
formulations
Fifty microliters of Tobra-SLN, corresponding to 0.15 mg of to-
bramycin, was administered in the lower conjunctival sac of both eyes
of each rabbit. The commercial product, Tobral®, used as control, was
administered at the same dose at a different groups of animals. At in-
tervals of 1 and 3 h the rabbits were euthanized with an intravenous
dose of sodium pentobarbital (Pentothal sodium, Farmaceutici Gellini,
Aprilia, Italy), the eyes enucleated and the tissues (vitreous and retina)
were collected and stored at −20 °C until quantitative analysis.
2.14. Antimicrobial activity and effects on polymorphonuclear
granulocyte (PMN) functions of Tobra-SOL and Tobra-SLN
The antimicrobial activity of tobramycin solution and Tobra-SLN
was evaluated measuring the Minimal Inhibiting Concentrations
(MICs) against a clinical isolate of P. aeruginosa by the standardized
dilution method in Mueller-Hinton broth (Unipath, Milan, Italy) with
an inoculum of 2 × 107 cfu/mL.
PMNs were separated from lithium heparinized venous blood [47]
using Ficoll-Paque (Pharmacia S.p.A., Italy). Using trypan blue test-
ing, the viability of PMNs was determined to be above 95%. PMNs
were suspended in RPMI 1640 medium with 10% fetal calf serum.
The interval between PMNs harvest and the start of experiments was
below 30 min. The effects of tobramycin solution and Tobra-SLN on
either the phagocytosis of radio-labeled P. aeruginosa [3H-uracil (spe-
cific activity: 1224.7 GBq/mmol; NEN Life, Italy)] or intracellular
bacterial killing by PMNs were investigated by incubating the bacte-
ria (2 × 107 cfu/mL) and the phagocytes (2 × 106 cells/mL) at 37 °C
in a shaking water bath for periods of 30, 60, or 90 min in the pres-
ence of the MIC of the drug. Antibiotic-free controls were also in-
cluded. Radioactivity was expressed as the counts per minute/sample.
The percentage of phagocytosis at a given sampling time was calcu-
lated as follows: percent phagocytosis = [(cpm in PMNs pellet)/(cpm
in total bacterial pellet)] × 100 [48,49]. The PMN killing values were
expressed as the Survival Index (SI), which was calculated by adding
the number of surviving bacteria at time zero to the number of sur-
vivors at time x, and dividing by the number of survivors at time zero.
According to this formula, if bacterial killing was 100% effective, the
SI would be 1.
To differentiate between any separate effect of Tobra-SOL and To-
bra-SLN on bacteria and PMNs, the experiments were conducted af-
ter exposing bacteria and PMNs separately to the antibiotics (1xMIC)
for 1.0 h, before they were incubated together [50]. After withdrawal
of the drug, pre-exposed bacteria were added to PMNs and bacteria
to pre-exposed PMNs. A control system was assayed in parallel with
no antibiotic. The phagocytic and bactericidal activities of PMNs were
determined as described above.
Each test was performed in triplicate; the results were compared
with those obtained with the control systems and are expressed as
means and standard errors of the means (SE) for ten separate experi-
ments.
2.15. Statistical analysis
The statistical difference between treatments was evaluated using
the Analysis of Variance (ANOVA) test. The evaluation included cal-
culation of the means and standard error and group comparison using
the Dunnett test. The confidence level was set at 95% and P ⩽ 0.05
was considered statistically significant.
3. Results and discussion
3.1. Characterization of Tobra-SLN
The average diameter, the polydispersity index (PI) and the zeta
potential (ζ) of tobramycin loaded SLN are reported in Table 1.
The SLN formulation showed a hydrodynamic diameter of
80.01 ± 11.10 nm with a PI value of 0.155 (± 0.03), representative of
a colloidal dispersion with high quality, characterized by an unimodal
relatively narrow size distribution In fact, even if PI values ⩽0.1 char-
acterize the highest quality of a colloidal dispersion, many researchers
indicate PI values ⩽0.3 as ideal index for an uniform system [51]. In-
terestingly, the slight increase of about 4% w/w of the amount of co-
surfactant in comparison with the previous formulation [24] produced
small, homogenous and physically stable nanodispersion. Indeed, the
negative zeta potential value (ζ = −25.7 ± 0.20 mV) was sufficiently
high to favor a high degree of repulsion among similarly charged SLN
particles and to guarantee the physical stability of the colloidal disper-
sion [51]. The standardization of the size of SLN as small nanopar-
ticles of 80.01 ± 11.0 nm seems promising to favor their penetration
into ocular structures (vitreous and retina).
Morphological analysis of Tobra-SLN in aqueous dispersions, de-
tected by TEM analysis, proved that most of the nanoparticles were
spherical in shape reaching several tens nanometers in their size, ac-
cording to the measurements performed by dynamic light scattering.
TEM photomicrograph for a Tobra-SLN sample is reported in Fig. 1.
The interactions among the different components of the To-
bra-SLN formulation detected by FTIR analysis, are shown in Fig.
2, where the spectrum of Tobra-SLN was compared with that of
stearic acid and tobramycin as ion-pair. The FTIR analysis of to-
bramycin showed absorption bands in the range between 1600 and
Table 1
Technological characteristics of the Tobra-SLN formulation: average diameter, poly-
dispersity index, zeta potential and amount of Tobramycin incorporated in freeze-dried
SLN (Means ± SD, n = 10).
Formulation
Average
diameter nm
(±SD)
Polydispersity
index
Zeta potential
mV (±SD)
Incorporated drug
(% w/w ± SD)
Tobra-SLN 80.01
(±11.10)
0.15
(±0.03)
−25.70
(±2.00)
2.50
(±0.18)
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Fig. 1. Transmission electron microphotograph of Tobra-SLN.
1300 cm−1 that could be attributed to NH group, CH2 scissoring, OH
bending and a strong absorption bands around 1000 cm−1 correspond-
ing to C O and C N bonds. These last absorption bands were ab-
sent in the spectrum of Tobra-SLN, that, on the contrary, was char-
acterized by typical peaks of stearic acid. In fact, in both spectra of
stearic acid and Tobra-SLN were detected absorption bands around
2800–3000 cm−1 and 1700 cm−1 corresponding to OH and C O
stretching frequency.
Therefore, it is plausible that tobramycin ion-pair is dispersed into
the lipid component of the lipid nanoparticle without interaction with
the stearic acid.
Thermal analysis was used to investigate the crystal structure of
tobramycin in SLN: the results of DSC analysis are shown in Fig.
3. The thermogram of tobramycin revealed a series of endothermic
peaks characterized by the fusion of metastable form and recrystalliza-
tion with a final melting peak at 217 °C. They were completely absent
in the curve of drug loaded SLN, where appeared exclusively the en-
dothermic peak at 69.25 °C corresponding to the fusion of stearic acid,
the main component of nanoparticle matrix. Indeed, the presence of
the drug, surfactant and cosurfactant in SLN decreased the fusion tem-
perature in comparison with pure stearic acid, as previously shown.
This thermal behavior suggests that the drug was completely solu-
bilized inside the matrix of the SLN and it was not able to crystallize,
in agreement with previous results with other formulations [52,53]
and it may be related to the preparation methods consisting in a rapid
quenching of a melt liquid. Additionally, tobramycin was still pre-
sent in the amorphous form or molecularly dispersed in SLN after
24 months from the preparation (data not shown). The increased solu-
bility of tobramycin in the lipophilic matrix, represents a positive as-
pect from the point of view of biopharmaceutical performance of the
preparation as discussed elsewhere [54] and could affect the drug re-
lease kinetic.
The quantitative analysis of tobramycin incorporated in
freeze-dried SLN proved that the concentration of tobramycin in SLN
was 2.5% w/w (see Table 1). The loading capacity might be suitable
for obtaining the 0.3% drug concentration currently used in therapeu-
tic treatment with commercial eye drops.
A large amount of mucin was absorbed on the Tobra-SLN sur-
face. Indeed, the mucin binding efficiency was about 87%. The mucin
absorption was confirmed by a marked decrease in the zeta potential
value (data not shown).
Therefore, morphological and physicochemical properties of the
solid lipid nanoparticles (average particle size, polydispersity index
and composition) made them suitable as release systems for oph-
thalmic administration. Interestingly, our group has previously shown
that SLN improved the drug passage across anatomical barriers, such
as the blood brain barrier, and could be used to prolong the release of
several drugs [24,27].
Fig. 2. FTIR spectroscopy analysis of Tobramycin as ion-pair, stearic acid and Tobra-SLN formulation.
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Fig. 3. DSC thermograms of Tobramycin, and Tobra-SLN and stearic acid.
3.2. In vitro release kinetics
The in vitro drug release profiles at pH 7.4 of drug from the To-
bra-SLN formulation are shown in Fig. 4. The analysis of the drug re-
lease showed a fast diffusion of the drug from the aqueous solution
(Tobra-Sol) and a controlled release rate from Tobra-SLN. The drug
release mechanism was studied using the semi-empirical power law
relationship proposed by Ritger and Peppas [45], Mt/M∞ = Ktn, where
Mt/M∞ is the fraction of drug released at each time point (t), k a kinetic
constant relative to the properties of the matrix and n is the release ex-
ponent, indicative of the mechanism of drug release. The data related
to SLN formulations fitted well into pseudo-zero order release kinet-
ics (n = 0.96, R2 = 0.996) with a cumulative percentage of tobramycin
released after 2 h of about 24% w/w with no initial burst effect. On
the contrary, after two hours from the beginning of the experiment, the
percentage of tobramycin recovered in the receiving compartment for
the reference aqueous solution (Tobra-SOL) was approximately 80%
w/w and the release kinetic followed a diffusive mechanism (n = 0.58;
R2 = 0.981).
Fig. 4. In vitro release profiles of Tobramycin from the Tobra-SLN formulation in
pH = 7.4 phosphate buffer (Means ± SD, n = 6).
The difference in kinetic behavior and in percentage of drug re-
leased is probably related to different lipophilicities of drug in the
preparation. In addition to tobramycin has a strong hydrophilic fea-
ture, incorporating it in SLN as an ion-pair with hexadecyl phosphate
to increase its lipophilicity, according to our previous study on pilo-
carpine [55], produced a promising sustained-release ocular formula-
tion. The lipophilic nature of tobramycin ion pair and its affinity for
the lipophilic component are also demonstrated by the absence of a
burst effect in the early stage of the in vitro release study, highlighted
in the literature for many types of SLN. The burst effect is often attrib-
uted to the presence of drug on the surface of the SLN, where the lipid
concentration is lower and the concentration of the surfactant is higher
[34,56]. In our case the tobramycin could be concentrated into lipid
inner matrix of SLN, thus promoting its slow and constant release in
the dissolution medium that could also occur in vivo after ocular or in-
travenous administration.
3.3. Physical and chemical stability of drug-loaded SLN over time
The results of the stability for Tobra-SLN formulation as aque-
ous dispersion stored at 4°C are reported in Table 2, where the main
technological parameters (average diameter, PI, ζ, and incorporated
drug) are reported vs time. The preparation showed good stability up
to 12 months with no aggregation or precipitation phenomena, varia
Table 2
Technological characteristics of the Tobra-SLN formulation: average diameter, polydis-
persity index, zeta potential and amount of Tobramycin incorporated into lyophilized
SLN during stability study, (Means ± SD, n = 10).
Technological parameters Time (months)
0 6 12 24
Average diameter
nm (±SD)
80.01
(±11.10)
83.01
(±14.10)
80.10
(±17.03)
120.10
(±18.04)
Polydispersity index 0.15
(±0.03)
0.15
(±0.06)
0.15
(±0.04)
0.18
(±0.05)
Zeta potential
(mV ± SD)
−25.7
(±2.0)
−25.9
(±2.0)
−24.5
(±1.7)
−22.8
(±0.6)
Incorporated drug
(% w/w)
2.50
(±0.18)
2.49
(±0.16)
2.48
(±0.19)
2.50
(±0.15)
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tions in zeta potential values or in amount of the drug encapsulated
into the nanoparticles.
Unexpectedly, their average diameters and PI values confirmed
the presence of an increase in SLN dimensions (about 30%) after
24 months (Table 2): the average diameters of Tobra-SLN increased
from 80 nm to 106 nm. However, the slight increase of PI, ranging
from 0.15 to 0.18 and the decrease of ζ up to −22.8 mV might not rep-
resent a significative instability of the formulation. In fact, the amount
of drug incorporated into Tobra-SLN formulation did not change after
24 months at 4 °C.
3.4. In vivo experiments: intravenous and ocular administration of
the formulations
As expected, Tobra-SLN formulation was well tolerated without
any symptoms of ocular inflammation and irritation in the different
eye tissues. This behavior agreed with experimental data reported in
our previous publication [27].
The concentration of tobramycin in the biological tissues (vitre-
ous humor and retina) 1.0 and 3.0 h after ocular or intravenous admin-
istration of the two formulations under study is summarized in Figs.
5–7 where the concentration of Tobramycin in the different tissues
collected from rabbits eye has been reported vs. time. The aqueous
Fig. 5. Tobramycin concentrations in the aqueous humor and vitreous humor 1 h and 3 h
after ocular administration of the formulations under study. The values are expressed as
means ± SD. ∗Significantly different (P < 0.01) from the Tobral®.
Fig. 6. Tobramycin concentrations in aqueous humor and vitreous humor 1 h and 3 h af-
ter intravenous administration of the formulations under study. The values are expressed
as means ± SD. ∗Significantly different (P < 0.01) from the Tobra-Sol (reference solu-
tion). ∗∗Significantly different (P < 0.02) from the Tobra-Sol.
Fig. 7. Tobramycin concentrations into the retina 1 h and 3 h after intravenous adminis-
tration of the formulations under study. The values are expressed as means ± SD.
humor data published in our previously paper are reported as a com-
parison [27].
Surprisingly, the drug concentration was significantly higher in all
ocular tissues (aqueous humor and vitreous humor and retina) after
instillation and intravenous administration of Tobra-SLN formulation
with respect to reference experimental formulations either commercial
eye drop (Tobral®) or Tobra-Sol. Furthermore, regardless of the route
of administration, exclusively the SLN formulation allowed an appre-
ciable penetration of tobramycin into posterior segment of the eye. In
the case of the solution, tobramycin was undetectable in the vitreous
humor at 3 h and in the retina at the time 1 h and 3 h, although the dose
administered was relatively high. Ocular administration of Tobra-SLN
produced a concentration of tobramycin in the aqueous humor twofold
and fivefold (P < 0.01) higher compared to those obtained for Tobral®
commercial preparation after 1 h and 3 h respectively. Any traces of
tobramycin were detected into vitreous humor and retina after instilla-
tion of Tobral®, while considerable amounts of the drug were found
into vitreous at both the selected times (30.6 μg/mL and 20.2 μg/mL
at 1 and 3 h, respectively) after SLN administration.
The drug recovery into retina was of 4.74 μg/g 1 h after instillation
of Tobra-SLN and about ten-fold lower after 3 h (0.571 μg/g) as re-
ported in Fig. 7.
A similar result was obtained after intravenous administration: in-
deed 1 and 3 h after injection of Tobra-SLN the concentrations of drug
in the aqueous humor were about ten times higher than those obtained
with the reference solution (Tobra-Sol) and a significant drug concen-
tration was detected at the same times into vitreous humor. The re-
sult achieved analyzing the retina was especially interesting, since To-
bla-SLN formulation allowed a high accumulation of drug in the retina
after 1 h and its amount was more than 3 times higher than that ob-
tained by instillation (17.2 vs 4.74 μg/g).
These data confirm our previous results and emphasize the suit-
ability of Tobra-SLN for an improvement of ocular drug bioavailabil-
ity by exploiting drug passage through anatomical barriers and pro-
longing drug release. These results seem in agreement with the hy-
pothesis that SLN could represent a versatile ocular drug delivery
for the treatment of anterior and posterior chamber pathologies both
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when topically and/or systemically applied. Numerous researchers
demonstrated through ex vivo permeation studies performed on cornea
of rabbits [20,23,31,57] that the cornea does not represent a substan-
tial barrier to permeation of drug loaded in SLN. In fact, SLN for their
lipophilic nature, favor drug permeation through the highly hydropho-
bic corneal epithelium and this behavior, in our case, could be sup-
ported by the considerable interaction with mucin, strictly depending
on the capability of the nanometric size carrier (80 nm) to remain en-
trapped among the mucopolysaccharide chains of mucin available in
the precorneal area. Furthermore, it cannot be excluded that the tran-
scleral route might contribute to drug absorption in vitreous humor
through the periocular route analogously to literature data [21,23,57].
In light of this hypothesis, also the constant drug release rate, con-
firmed by in vitro data without any burst effect, could be a positive
factor able to increase the ocular drug bioavailability. Indeed, the con-
stant and sustained drug release from the lipid matrix over time en-
sures the maintaining of a constant drug concentration gradient and
consequently the presence of a drug reservoir available for corneal and
eventually scleral diffusion.
Considering the above mentioned aspects, our new pharmacoki-
netic data after topical instillation of Tobramycin entrapped SLN al-
low to hypothesize that both trans-corneal diffusion followed by entry
into vitreous and subsequent distribution to ocular tissues (trans-vitre-
ous route) and probably drug diffusion around the sclera followed by
trans-scleral absorption (periocular route) might be the mechanisms to
achieve the posterior segment of the eye [58].
On the other hand, several recently published studies describe the
capability of systemically administered nanosystems as SLN [59–61]
to overcome important physiological barriers. The higher amount of
Tobramycin in the retina after systemic administration of the To-
bra-SLN formulation with respect to ocular instillation, could be as-
cribable to the presence of the high vasculature of choroid that, with its
fenestrated choriocapillaris, determines a rapid equilibration of drug
molecules present in the bloodstream with the extravascular space.
Through this route and by-passing the blood–retinal barrier, which re-
strict the movement of the substances to the intraocular spaces, the
achievement of therapeutic levels of drug in the intraocular tissues
might be reached [3,62,63].
3.5. Antimicrobial activity and effects of Tobra-Sol and Tobra-SLN
on polymorphonuclear granulocyte (PMN) functions
The MIC of tobramycin solution (Tobra-Sol) for the clinical strain
of P. aeruginosa was found to be 4.0 μg/mL, whereas that for To-
bra-SLN it was 2.0 μg/mL. PMN viability remained unchanged
throughout the experiments. Table 3 shows the in vitro effects of to-
bramycin solution and Tobra-SLN on phagocytosis and killing of in-
tracellular bacteria by PMNs. The presence of 1x MIC of tobramycin
solution and Tobra-SLN exerted little effect on the human granulo-
cyte phagocytosis, resulting in a slightly increased percentage of in-
gested Pseudomonas, in comparison with controls (Table 3; columns
A, A1). Incubation of PMNs containing intracellular P. aeruginosa
in either an antibiotic-free control culture or in the presence of to-
bramycin enabled the bacteria to increase in number grown: SI val-
ues were >2, which is compatible with intracellular survival (Col-
umn D). Conversely, Tobra-SLN added to PMNs after phagocytosis
had occurred significantly enhanced intracellular microbicidal activ-
ity against ingested Pseudomonas: during the 90-min period the in-
tracellular bacterial load was reduced, achieving 53–70% of killing
(P < 0.01; Table 3; Column D1).
To investigate the direct effect of the two formulations on the
phagocyte functions, bacteria and human PMNs were pre-incubated
for 1 h with 1xMIC of Tobra-Sol or Tobra-SLN. After withdrawal of
the antibiotic, bacterial uptake and microbicidal activity were deter-
mined. Tobramycin pre-treatment of the bacteria during their growth
phase had no effect on phagocytosis itself (Column B). Conversely
Tobra-SLN pre-treatment of bacteria led to a significant increase in
the phagocytic capability of PMNs, after 30 min of incubation
(P < 0.05; Column B1). Pre-treatment of P. aeruginosa for 1 h with
1xMIC of Tobra-Sol or Tobra-SLN markedly increased the microbi-
cidal activity of PMNs throughout the entire 90 min period of obser-
vation. However, much higher percentages of tobramycin-pretreated
Pseudomonas were killed by the PMNs compared with their To-
bra-SLN-treated counterparts: 75–69–54% versus 48–32–16%
(P < 0.01) (Column E, E1).
Pre-exposure of the PMNs to 1xMIC of tobramycin solution and
Tobra-SLN for 60 min did not affect their phagocytic capacity: the
Table 3
Effect of 1XMIC of tobramycin (Tobra-Sol) and Tobra-SLN on human PMN phagocytosis and intracellular killing of P. aeruginosa (Means ± SEM).
Time (min) % Phagocytosis Survival Index (%)
Controls A B C Controls D E F
Tobra-Sol Tobra-Sol
30 8.3 ± 0.3 9.42 ± 0.1 8.4 ± 0.2 7.88 ± 0.15 >2 >2 1.25b ± 0.07
(75%c)
>2
60 7.8 ± 0.37 7.8 ± 0.03 7.5 ± 0.04 7.61 ± 0.02 >2 >2 1.31b ± 0.09
(69%)
>2
90 4.8 ± 0.2 7.1 ± 0.34 5.0 ± 0.3 5.3 ± 0.06 >2 >2 1.46b ± 0.12
(54%)
>2
A1 B1 C1 D1 E1 F1
Tobra-SLN Tobra-SLN
30 8.3 ± 0.3 9.97 ± 0.05 12.8a ± 0.9 8.15 ± 0.18 >2 1.47b ± 0.12
(53%)
1.52b ± 0.10
(48%)
1.60b ± 0.06
(40%)
60 7.8 ± 0.37 6.02 ± 0.4 8.7 ± 0.09 7.85 ± 0.09 >2 1.37b ± 0.11
(63%)
1.68b ± 0.09
(32%)
1.68b ± 0.03
(32%)
90 4.8 ± 0.2 6.4 ± 0.26 6.97a ± 0.05 4.9 ± 0.25 >2 1.3b ± 0.05
(70%)
1.84b ± 0.09
(16%)
1.7b ± 0.15
(30%)
A,A1, D, D1: addition of Pseudomonas and 1xMIC of tobramycin solution or Tobra-SLN to PMNs; B,B1, E,E1: addition of bacteria to PMNs following 1 h pre-exposure of
Pseudomonas to 1xMIC of tobramycin solution or Tobra-SLN; C,C1, F,F1: addition of bacteria to PMNs following 1 h pre-exposure of phagocytes to 1xMIC of tobramycin solution
or Tobra-SLN.
a Significantly different (P < 0.05) from the controls.
b Significantly different (P < 0.01) from the controls.CPercentage of initial bacterial population killed by PMNs
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bacteria were phagocytosed by PMNs at a rate that was similar to that
in the controls (Column C, C1). In contrast, an enhanced bactericidal
effect by PMNs occurred with Tobra-SLN-pretreated PMNs, leading
to a significant decrease in SIs at all three time-points compared with
controls and tobramycin-pretreated PMNs (P < 0.01; Column F, F1).
The efficacy of an antibiotic in treating bacterial infections de-
pends upon the interaction of bacterium, drug and phagocytes [47–49].
Current trends require the use of antibiotics that combine good an-
timicrobial properties with the capacity to act in concert with the im-
mune system, in a way that potentiates the host’s defense mecha-
nisms [64]. Aminoglycosides penetrate little into cells and the high
doses required to carry a risk of drug toxicity. The use of Tobra-SLN
may result in both higher intraphagocytic antibiotic concentrations in
PMNs and greater bactericidal activity against intracellular P. aerug-
inosa, in comparison with the use of free tobramycin. This marked
bactericidal efficacy is probably related to the ability of Tobra-SLN
to penetrate either into phagocytic cells, or alternatively to cross bac-
terial barriers such as the outer membrane, in its active form, without
undergoing enzymatic attack. These data suggest that incorporation of
tobramycin into delivery systems could be essential to obtain a supe-
rior therapeutic effect.
These findings confirm the results reported in the literature: it has
been recently demonstrated that the complexation of antimicrobial
agents with amphiphilic moieties was able to maintain, and in partic-
ular condition to increase the antibacterial activity of the free drugs
[65].
4. Conclusion
Current treatment of ocular infections is primarily based on the
topical administration of appropriate anti-infective agents. Aminogly-
cosidic antibiotics, in particular tobramycin, are often prescribed to
eradicate external ocular infections, because of its marked activity
against Pseudomonas aeruginosa.
The success of antibacterial therapy depends on several features of
the antibiotics, as well as on the ophthalmic vehicle. In this paper, oc-
ular instillation of Tobra-SLN into the rabbit eye determined high con-
centration of tobramycin in both vitreous humor and retina, while any
amount of tobramycin was found in these ocular tissues after admin-
istration of commercial Tobral® eye drops. In addition, similar results
were obtained after intravenous injection of Tobra-SLN.
In conclusion, the present study demonstrates that the incorpora-
tion of tobramycin into small, homogeneous and mucoadhesive SLN
increases drug penetration into eye structures, maintaining sufficiently
high levels of drug in the aqueous humor, vitreous humor and retina,
not only after parenteral but also after ocular administration.
To our knowledge, these findings on the use of a stable SLN for-
mulation as a sustained drug carrier for ocular delivery to the posterior
chamber might open new avenues for ocular infections also consider-
ing that nanocarriers might represent a strategy to overcome the mi-
crobial resistance and to ameliorate the patient compliance.
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